Oral Minoxidil VDPHL01 Hits Phase 2/3 Endpoint in Hair Loss

Veradermics announced positive Phase 2/3 topline results on Monday for VDPHL01, a proprietary extended-release oral minoxidil designed specifically for pattern hair loss. In a 519-patient trial of men with mild-to-moderate androgenetic alopecia, the once-daily 8.5 mg dose produced a mean increase of 30.3 non-vellus hairs per square centimeter at month 6, while the twice-daily arm reached 33.0 hairs per square centimeter. Placebo recipients gained 7.3 hairs per square centimeter over the same period. No treatment-related serious adverse events and no cardiac adverse events of special interest were reported.

If the drug clears Phase 3 and FDA review, it would be the first oral medication approved for pattern hair loss in nearly three decades. Finasteride, the last oral hair-loss drug to win FDA approval for this indication, was cleared in 1997. The pipeline activity in alopecia has intensified across mechanisms in recent months, including a topical PROTAC degrader for AGA and a regulatory T-cell therapy for alopecia areata, but VDPHL01 is the first oral candidate to hit a Phase 2/3 endpoint in the male pattern indication.

Why Oral Minoxidil Is Suddenly Everywhere in Dermatology

Topical minoxidil has been an over-the-counter standard since the late 1980s, but the oral form was originally approved as a blood pressure medication in 1979. Dermatologists have prescribed it off-label for hair loss for years, and the practice has accelerated since 2021, when a multicenter study of 1,404 patients in the Journal of the American Academy of Dermatology established that low doses are generally well tolerated for hair loss.

The off-label boom exposed a gap. Generic immediate-release oral minoxidil was never engineered for dermatologic use. It reaches peak plasma concentration within an hour and clears materially within four hours, producing a sharp pharmacologic spike that has been associated with tachycardia and other cardiovascular effects in published case literature. A 2024 narrative review in the American Journal of Clinical Dermatology described pericardial effusion case reports in young, previously healthy patients on doses as low as 1.25 mg.

VDPHL01 is the first oral minoxidil designed around the constraints of dermatologic dosing rather than antihypertensive dosing.

How Does Extended-Release Minoxidil Work Differently?

VDPHL01 is encapsulated in a sustained-release gel matrix that dissolves gradually, releasing minoxidil over several hours rather than as a single bolus. Phase 1 pharmacokinetic data showed prolonged systemic exposure with attenuated peak concentrations, a profile intended to keep plasma levels above the threshold required for follicular stimulation while staying below the concentration associated with cardiac activity.

The mechanistic rationale runs deeper than smoothing the curve. Minoxidil is a prodrug that must be converted to its active form, minoxidil sulfate, by sulfotransferase enzymes (primarily SULT1A1) in the outer root sheath of the hair follicle. That enzymatic conversion is capacity-limited and time-dependent. A rapid systemic spike can outpace SULT1A1 activity in the follicle, while the short residence time of immediate-release minoxidil leaves limited duration for sustained conversion.

Veradermics has framed VDPHL01's pharmacokinetic profile as designed to better match the enzymatic kinetics of follicular activation. Whether that translates into a meaningful clinical advantage over carefully dosed off-label generic minoxidil is a question the Phase 3 program will need to answer.

The Numbers Behind the Trial

Study 302 randomized 519 male adults aged 18 to 65 with mild-to-moderate androgenetic alopecia to one of three arms: VDPHL01 8.5 mg once daily, VDPHL01 8.5 mg twice daily, or placebo. The co-primary endpoints were change from baseline in non-vellus target area hair count by digital image analysis at month 6, and the proportion of patients reporting "improved" or "much improved" on the Androgenetic Alopecia Impact Rating Scale at the same timepoint.

According to the Veradermics press release, both co-primary endpoints were met. Hair count results were 30.3 hairs per square centimeter for the once-daily arm, 33.0 for the twice-daily arm, and 7.3 for placebo. The patient-reported outcome data showed a similar pattern, with treatment arms outperforming placebo, though Veradermics has not yet released the precise percentages for the AAIRS endpoint.

On safety, the company reported overall treatment-emergent adverse event rates similar between VDPHL01 and placebo, lower discontinuation rates in the active arms than in placebo, and no cardiac adverse events of special interest. Detailed safety tables are expected at an upcoming medical meeting.

When Could VDPHL01 Reach Patients?

Veradermics is structuring Study 302 as a Phase 2/3 hybrid, with Part B continuing to longer-term endpoints. The company has not announced an FDA submission timeline. A new chemical entity in the AGA category would face standard FDA review, with potential approval likely no earlier than late 2027 if the program proceeds without regulatory delays.

The female pattern hair loss population represents a separate regulatory pathway. Veradermics has previously stated that VDPHL01 is being developed for both male and female pattern hair loss, but Study 302 enrolled only men. A female-specific trial would be required to support a broader label.

For the practicing dermatology audience, the more immediate question is what Phase 3 data show on direct comparisons, longer follow-up, and the durability of hair count gains beyond six months. The current readout establishes the molecule's activity. The next phase will determine whether it earns a place in the standard treatment algorithm.